Cargando…

Mesothelin Expression in Patients with High-Grade Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates with CD11c(+) Expression in Tumor

INTRODUCTION: Mesothelin (MSLN) is overexpressed in several tumors including ovarian cancer and is the target of current trials. There is limited and conflicting data on MSLN prognostic impact in ovarian cancer. METHODS: We performed a retrospective study on patients with high-grade serous ovarian c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Magalhaes, Isabelle, Fernebro, Josefin, Abd Own, Sulaf, Glaessgen, Daria, Corvigno, Sara, Remberger, Mats, Mattsson, Jonas, Dahlstrand, Hanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595982/ https://www.ncbi.nlm.nih.gov/pubmed/33052561 http://dx.doi.org/10.1007/s12325-020-01520-w

Ejemplares similares

The Role of Mesothelin Expression in Serous Ovarian Carcinoma: Impacts on Diagnosis, Prognosis, and Therapeutic Targets
por: Giordano, Giovanna, et al.
Publicado: (2022)

Mesothelin-Specific Immune Responses and Targeted Immunotherapy for Mesothelin-Expressing Tumors
por: Einama, Takahiro, et al.
Publicado: (2017)

Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer
por: Fransson, Åsa, et al.
Publicado: (2016)

Integrative approach to cytologic and molecular diagnosis of malignant pleural mesothelioma
por: Hjerpe, Anders, et al.
Publicado: (2020)

Liver myofibroblasts of murine origins express mesothelin: Identification of novel rat mesothelin splice variants*
por: Fausther, Michel, et al.
Publicado: (2017)

Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo
por: Ye, Lin, et al.
Publicado: (2019)

An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin
por: Snell, Daniel, et al.
Publicado: (2023)

Markers of fibroblast-rich tumor stroma and perivascular cells in serous ovarian cancer: Inter- and intra-patient heterogeneity and impact on survival
por: Corvigno, Sara, et al.
Publicado: (2016)

The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors
por: Yu, Yi, et al.
Publicado: (2011)

Utility of BerEp4/calretinin and desmin/epithelial membrane antigen (EMA) dual immunocytochemical staining in effusion cytology
por: Hjerpe, Anders, et al.
Publicado: (2022)

Spatially resolved transcriptomics of high-grade serous ovarian carcinoma
por: Stur, Elaine, et al.
Publicado: (2022)

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma
por: Tholander, Bengt, et al.
Publicado: (2020)

Fibulin1 and mesothelin expressions in pancreas ductal adenocarcinoma
por: Aksoy, Asude, et al.
Publicado: (2023)

Favorable therapeutic response after anti-Mesothelin antibody–drug conjugate treatment requires high expression of Mesothelin in tumor cells
por: Lazzerini, Lea, et al.
Publicado: (2020)

Mesothelin Expression in Gastric Adenocarcinoma and Its Relation to Clinical Outcomes
por: Han, Song-Hee, et al.
Publicado: (2017)

High Homogeneity of Mesothelin Expression in Primary and Metastatic Ovarian Cancer
por: Weidemann, Sören, et al.
Publicado: (2023)

Oral mucositis after tacrolimus/sirolimus or cyclosporine/methotrexate as graft‐versus‐host disease prophylaxis
por: Garming Legert, Karin, et al.
Publicado: (2020)

ERC/mesothelin is expressed in human gastric cancer tissues and cell lines
por: ITO, TOMOAKI, et al.
Publicado: (2014)

Importance of luminal membrane mesothelin expression in intraductal papillary mucinous neoplasms
por: EINAMA, TAKAHIRO, et al.
Publicado: (2015)

Host Mesothelin Expression Increases Ovarian Cancer Metastasis in the Peritoneal Microenvironment
por: Hilliard, Tyvette S., et al.
Publicado: (2021)

Level of mesothelin expression can indicate the prognosis of malignant pleural mesothelioma
por: Feng, Feifei, et al.
Publicado: (2020)

Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease
por: Schain, Frida, et al.
Publicado: (2020)

Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma
por: Norris, Eric J, et al.
Publicado: (2019)

Prognostic gene expression signature for high-grade serous ovarian cancer
por: Millstein, J., et al.
Publicado: (2020)

Significance of mesothelin expression in preoperative endoscopic biopsy specimens for colorectal cancer prognosis
por: Shiraishi, Takehiro, et al.
Publicado: (2020)

Significance of mesothelin and CA125 expression in endometrial carcinoma: a retrospective analysis
por: Kakimoto, Soichiro, et al.
Publicado: (2021)

Population-based real-world registry study to evaluate clinical outcomes of chronic graft-versus-host disease
por: Novitzky-Basso, Igor, et al.
Publicado: (2023)

Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma
por: Lara, Olivia D., et al.
Publicado: (2019)

Molecular Profiles of Serum-Derived Extracellular Vesicles in High-Grade Serous Ovarian Cancer
por: Zhao, Li, et al.
Publicado: (2022)

Targeting mesothelin in ovarian cancer
por: Ghafoor, Azam, et al.
Publicado: (2018)

Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin
por: Liu, Xiufen, et al.
Publicado: (2022)

High expression of Tie-2 predicts poor prognosis in primary high grade serous ovarian cancer
por: Sopo, Minna, et al.
Publicado: (2020)

Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer
por: Einama, T, et al.
Publicado: (2012)

Mesothelin expression and its prognostic role according to microsatellite instability status in colorectal adenocarcinoma
por: Kim, Hyunsung, et al.
Publicado: (2019)

Possible reversibility between epithelioid and sarcomatoid types of mesothelioma is independent of ERC/mesothelin expression
por: Kojima, Masataka, et al.
Publicado: (2020)

Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors
por: Weidemann, Sören, et al.
Publicado: (2021)

Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies
por: Benloucif, Abdennour, et al.
Publicado: (2023)

Similar protein expression profiles of ovarian and endometrial high-grade serous carcinomas
por: Hiramatsu, Kosuke, et al.
Publicado: (2016)

CCNE1 expression in high grade serous carcinoma does not correlate with chemoresistance
por: Sapoznik, Stav, et al.
Publicado: (2017)

Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment
por: Zhang, Xianyu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_577vkrv7j4vsjfg3dfjp6si7ib